| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444344 | European Journal of Cancer | 2013 | 9 Pages |
Abstract
AVE1642 is well tolerated as a single agent and combined with D. The selected dose of AVE1642 combined with D is 6Â mg/kg. Promising activity was seen in sarcoma and breast cancer patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean Charles Soria, Christophe Massard, Vladimir Lazar, Marie-Laure Ozoux, Dominique Mery-Mignard, Antoine Deslandes, Anthony W. Tolcher,